

WELCOME

From the Wild West to the Next Frontier



Disclosures

Consultant for Biosense Webster

Question 1

What is the current state of pacing?

Response

- A. Pacing is a mature technology with little or no chance of improvement
- B. Pacing is an exciting subject with innovations on the horizon
- C. Pacing is gradually evolving

3 Problems with Cardiac Devices

♥ Leads

- leadless pacemakers, transthoracic pacing

♥ Batteries

- batteryless pacemakers or biological pacemakers


♥ Dyssynchrony caused by RV pacing resulting in heart failure associated with pacing

- Optimize LV pacing via the CS
- Utilize HIS bundle for intrinsic (native) activation

♥ Device Management for safety

Leadless pacing

- ♥ Most of the complications from pacing arise from the leads and pocket
 - Hematoma, infection, erosion, pneumothorax, fracture, threshold rise
- ♥ Micra MDT, Nanostim SJM
 - Leadless devices
 - Venous access from the groin
 - Active fixation battery, lead and computer all in one.



Micra Results

- ♥ 724 patients with class I or II indications for ventricular pacing (VVIR)
 - 99.2% were successfully implanted
- ♥ 6 month- 96% patients were free of complications
- ♥ Compared with 2667 historical controls
 - Fewer complications- hospitalizations, revisions
 - Similar anticipated battery life based on thresholds
 - No embolization, rare retrieval (n=1)

Ritter, P, *NEJM*, 374(6); 533-41

Future directions

- ♥ Atrial and ventricular dual chamber device with blue tooth device- device communication.
- ♥ Intracardiac portion of s-ICD- ATP and back up pacing
- ♥ Limitations
 - Thresholds
 - Battery changes

Batteryless Pacing


- ♥ Cardiac and pulmonary motion represent unlimited supply of energy for pacing.
- ♥ Harvesting cellular resources to accomplish this goal
- ♥ Nanowire with a pizo-electric crystal which when moved generates 1-2 V and up to 100mA.
- ♥ Device testing currently in animals.

Friedman, P et al, *JACC*, 69(2):2011-35, Jan 2017

Cardiac Resynchronization

♥ Limitations:


- Anatomy of the CS- dependent on branches
- High LV thresholds (pacing from a vein)
- Nonresponders



Friedman, P et al, *JACC*, 69(2):2011-35, Jan 2017

Multipoint pacing

- ♥ Quadripolar LV lead
- ♥ Paces LV1, LV2 and RV
- ♥ 90% patients have better LV performance with multipoint LV pacing
- ♥ Improves prior nonresponders
- ♥ Uses more energy from the battery.




Zanon, F et al, *Heart Rhythm* 12 (5):975-81, May 2015

Adaptive CRT

- ♥ Device based algorithm for patients with LBBB
- ♥ Utilizes native RBB for RV activation and LV lead for LV activation
- ♥ Less energy expended for cardiac activation
- ♥ Results in higher % of responders

HIS Bundle Pacing

- ♥ AVNode → HIS bundle → Left and Right Bundles → Fascicular system
- ♥ 75% of AV block- intra-HIS or proximal disease
 - age-related
 - mechanical
 - auto-immune
- ♥ Distal disease- HIS pacing not possible
 - usually CAD and scar related




HIS Bundle Pacing



- ♥ Fixed curve catheter
- ♥ 4FR 3830 lead, select secure
- ♥ Unipolar recording to record HIS bundle
- ♥ Active fixation

EGMs, Xray


EGM from HBP lead outside the sheath



EGM from HBP lead after fixation



Dandamudi, G et al, *PACE* 39 (2016): 1298-1304



Makishima, N, *J of Arr* 32 (2016): 499-501

Pros/Cons

♥ Pros

- Provides equal or improved LV function in pacing induced or LBBB relate cardiomyopathy
- Simpler procedure, more reproducible


♥ Cons

- Slightly higher than normal thresholds
- Lower than normal sensing
- Lumenless lead
- Higher rates of revision

NMHI HIS Bundle Experience

- ♥ 22 devices (>3 months post implant)
- ♥ 2 not using the HIS lead because of high thresholds
- ♥ 2 revisions
- ♥ Average threshold 1.5@1.0ms
- ♥ 6 leads with back up pacing
- ♥ 16 without

Remote Device Management




Friedman, P et al, *JACC*, 69(2):2011-35, Jan 2017

NMHI Experience

- ♥ 2487 patients followed in our device clinic
- ♥ 70% of pacers and 80% of ICDs enrolled in remote monitoring.
- ♥ Compared 1400 patients from 2010 to 2014 enrolled in remote monitoring to a national pool from the Merlin (SJM) database.

Overall Survival

Mortality Ratio of Clinics for Implants Between 2010-2014



Device Longevity

Device Type	Clinic Longevity	National Average	Increase	p-value
CRT-D	6.8 +/- 1.1 years	6.1 years	13%	p < 0.001
ICD-DR	7.9 +/- 0.9 years	7.5 years	5%	p < 0.001
ICD-VR	9.1 +/- 0.8 years	8.7 years	4%	p < 0.001
CRT-P	8.1 +/- 1.9 years	6.8 years	19%	p < 0.001
Pacer-DR	10.1 +/- 1.7 years	9.0 years	12%	p < 0.001
Pacer-SR	11.7 +/- 1.6 years	10.6 years	10%	p < 0.001

Guideline Based Programming

- ♥ Guidelines recommend three zones
- ♥ Guidelines recommend a monitor zone

